Press Release | NeoGenomics Laboratories

March 13, 2023

NeoGenomics Expands NGS Portfolio with Launch of Neo Comprehensive(TM) - Solid Tumor CGP and Neo Comprehensive(TM) - Myeloid Disorders CGP

February 28, 2023

NeoGenomics to Present at the 44th Annual Raymond James Institutional Investors Conference

February 23, 2023

NeoGenomics Reports Fourth Quarter and Full Year 2022 Results

February 6, 2023

NeoGenomics Schedules its Fourth Quarter and Full Year 2022 Earnings Release for February 23, 2023

February 6, 2023

RaDaR® Assay Demonstrates Clinical Potential for Helping Oncologists Determine Whether or Not Muscle-Invasive Bladder Cancer Patients Undergo Radical Surgery

December 5, 2022

NeoGenomics Announces Chief Financial Officer Transition

December 5, 2022

NeoGenomics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 21, 2022

RaDaR(R) Assay Demonstrates Clinical Potential for Detecting Disease Recurrence Across All Types of Early Breast Cancer, Including Triple Negative Disease

Contact Us To Get Started!

Work with us – your premier oncology partner – to optimize cancer care for patients